Shots:
- Pharming Group has launched Joenja in Japan for activated PI3K delta syndrome (APDS) patients aged 4 years and older following NHI reimbursement listing
- As per the agreement with Pharming, OrphanPacific serves as Joenja’s Marketing Authorization Holder in Japan &, alongside Pharming, manages the product’s supply & distribution
- Leniolisib is under regulatory review for pediatric APDS in several countries and is also being evaluated in two P-II trials for primary immunodeficiencies with immune dysregulation
Ref: Pharming Group | Image: Pharming Group | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
